



Published in final edited form as:

Mol Cancer Ther. 2019 November ; 18(11): 1899–1908. doi:10.1158/1535-7163.MCT-19-0208.

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications

Samantha A. Armstrong¹, Christopher W. Shultz², Ariana Azimi-Sadjadi¹, Jonathan R. Brody², Michael J. Pishvaian³

¹Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.

²The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, and the Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

³The University of Texas, MD Anderson Cancer Center

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies with very few therapeutic options to treat advanced or metastatic disease. The utilization of genomic sequencing has identified therapeutically relevant alterations in ~25% of PDAC patients, most notably in the DNA damage response (DDR) genes rendering cancer cells more sensitive to DNA damaging agents, and DNA damage response inhibitors, such as PARP inhibitors. ATM is one of the most commonly mutated DDR genes, with somatic mutations identified in 2 – 18% of PDACs and germline mutations identified in 1 – 34% of patients with PDAC. ATM plays a complex role as a cell cycle checkpoint kinase, regulator of a wide array of downstream proteins, and responder to DNA damage for genome stability. The disruption of ATM signaling leads to downstream reliance on ATR and CHK1 among other DNA repair mechanisms, which may enable exploiting the inhibition of downstream proteins as therapeutic targets in *ATM*-mutated PDACs. In this review we will detail the function of ATM, review the current data on ATM-deficiency in PDAC, examine the therapeutic implications of ATM alterations, and explore the current clinical trials surrounding the ATM pathway.

Corresponding author: Michael J. Pishvaian, MD, PhD, The University of Texas, MD Anderson Cancer Center. 1515 Holcombe Blvd, Unit 426, FC10.2004, Houston, TX 77030. Phone: 713-792-0759. Fax: 713-745-1163. MPishvaian@mdanderson.org.

Authors' Contributions:

Samantha Armstrong: Planning, conduct, and reporting of the work described in the article

Christopher Shultz: Planning, conduct, and reporting of the work described in the article

Ariana Azimi-Sadjadi: Planning, conduct, and reporting of the work described in the article

Jonathan R. Brody: Planning, conduct, and reporting of the work described in the article

Michael J. Pishvaian: Planning, conduct, and reporting of the work described in the article; responsible for the overall content as guarantor.

Authors' disclosures of potential conflicts of interest:

Samantha Armstrong: None

Christopher Shultz: None

Ariana Azimi-Sadjadi: None

Jonathan R. Brody: Scientific Advisory Board for Perthera

Michael J. Pishvaian: None directly related to this work. Dr. Pishvaian does have the following conflicts to report: **Speaker/Consultant:** AstraZeneca/MedImmune, Caris Life Sciences, Celgene, Merrimack, Perthera, RenovoRx and Sirtex Medical. **Travel, Accommodations and Expenses Support:** AstraZeneca/MedImmune, Caris Life Sciences, Perthera and Sirtex Medical. **Stock:** Perthera. **Research Funding to my Institution:** ARMO BioSciences, Bavarian Nordic, Bayer, Bristol-Myers Squibb, Calithera Biosciences, Celgene, Celldex, Curegenix, Fibrogen, Genentech, Gilead Sciences, GlaxoSmithKline, Halozyme, Karyopharm Therapeutics, MedImmune, Merck, Novartis, Regeneron, Pfizer, Pharmacylics and Tesaro.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies with fewer than 10% of patients surviving 5 years. Disease incidence is increasing and PDAC is projected to be the second most common cause of cancer-related death by 2030 (1,2). The high mortality is due to the majority of patients presenting with locally advanced or metastatic disease at the time of diagnosis. Unfortunately, despite recent improvements in outcomes with newer chemotherapy regimens, the median survival remains less than one year (3,4). Comprehensive genetic analysis is being pursued to identify mutational pathways for potential treatment options, and a recent study utilizing genomic sequencing identified therapeutically relevant (highly actionable) alterations in 27% of PDAC samples (5). These findings were consistent with several other publications, all of which have demonstrated findings of actionable targets in 17–48% of PDAC samples (6–11). One commonality to these large-scale next generation sequencing efforts is the identification of mutational defects in the genes that regulate the DNA damage response and repair (DDR) system, found in 17–25% of PDACs.

During the cell cycle, there is a replication of over six billion base pairs of DNA. Such genomic replication is subject to numerous insults and replication stressors, which rely on essential response and repair mechanisms to ensure DNA's integrity. Furthermore, the chemotherapies used to treat cancers, particularly pancreatic cancer, result in specific types of DNA damage. For example, alkylating agents such as platinum, and topoisomerase inhibitors such as irinotecan cause double-strand DNA breaks (DSBs); while anti-metabolites such as 5-fluorouracil and gemcitabine cause single base pair damage that can lead to single strand DNA breaks (12). Deficiencies in DDR mechanisms have revealed targets for therapy and research has led to FDA approved treatments targeting cancers that harbor such deficiencies. For example, BRCA1 and BRCA2 play an integral role in the maintenance of genomic integrity, and germline mutations in either gene leads to increased risks for breast, ovarian, pancreatic, and prostate cancers (13). However, the presence of a *BRCA1/2* mutation also predicts for an improved response and improved overall survival with platinum-based chemotherapy in both triple negative breast cancers as well as PDAC (14,15). Exploiting this DNA repair defect not only improves sensitivity to chemotherapy, but also allows targetable therapy through the inhibition of the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP), leading to the accumulation of single strand breaks which compromise DNA double strand integrity at the replication fork. PARP inhibitors increase progression free survival in advanced *BRCA1/2* mutated ovarian and breast cancer (16–18), and are now FDA approved for these diseases. Additionally, responses to PARP inhibitors are also frequently seen in *BRCA* mutated castrate resistant prostate cancer with, for example, a response rate of 88% in a 50 patient trial; and in *BRCA* mutated pancreatic cancer, with responses of 16 to 22% in small trials of 19 and 23 patients, respectively (16,19–21).

ATM also plays a critical role in DDR. The ataxia telangiectasia mutated (ATM) gene, located on chromosome 11q 22–23, was first identified in 1995 during the evaluation of the ataxia telangiectasia syndrome. Germ-line mutations of *ATM* result in a well-characterized

syndrome, as well as an increased predisposition for breast, pancreatic, and prostate cancers (22–28). Relevant here, mutations in the *ATM* gene, whether germline or somatic are found in up to ~6% of PDACs (further details below), and thus may represent a more prevalent DDR mutation than *BRCA1/2* (7). In this review, we will detail the function of ATM, review the current data on ATM-deficiency in PDACs, and examine the therapeutic implications of ATM alterations.

Function of ATM

The ATM gene consists of 66 exons that encode a PI3K-related serine/threonine protein kinase that plays a central role in the response to, and ultimately the repair of DNA double-strand breaks (DSB). Structurally, this large protein (350kDa) contains serine or threonine residues susceptible for phosphorylation, followed by a glutamine amino acid located near its hydrophobic target region. Similar sites for post-translational modifications (PTMs) are found in the ataxia telangiectasia and RAD 3-related (ATR) kinase and in the DNA protein kinase (DNA-PK) proteins (29). ATM has important functions in the cell including the maintenance of: i) telomere length (30,31); and ii) the mitotic spindle structure during mitosis (32). However, this review will solely focus on the central role of ATM in the process of DDR, including as it relates to targeted therapies in cancer. As depicted in Figure 1, in order to repair damaged DNA, the MRE11-RAD50-NBS1 (MRN) complex acts as the primary sensor for DSBs and creates a physical bridge between the two broken ends (33). ATM can then interact directly with NBS1 (part of the MRN complex) through the direct binding of the C-terminus of NBS1 to several of the HEAT repeats that reside in ATM (34). It is believed that several PTMs are required for subsequent ATM activation. For instance, ATM has been shown to be activated through acetylation of K3016 by TIP60, a histone acetyltransferase that binds to ATM through recognition of the C-terminal FATC domain (35). ATM also requires autophosphorylation at S1981, which allows the kinase domain to dissociate from the FAT domain, enabling, in turn, the kinase to become active (36). These modifications allow ATM to transition from an inactive homodimer into an active monomer in response to DNA damage (36). This mechanism has been supported in the literature, but also questioned by others, demonstrating the need for further work in the field to clearly identify the role of S1981 and other ATM autophosphorylation events (29,36,37). Once activated, ATM phosphorylates multiple substrates, protein kinases, and sensor proteins in order to carry out DSB repair and also regulate normal cell cycle processes, such as apoptosis and checkpoint activation (36,38,39).

ATM plays a role in the signaling required to initiate DNA repair, and thus, ATM defects can lead to genomic instability and malignancy. Hereditary and sporadic *ATM* mutations span the functional domains of the entire *ATM* gene (Figure 2). These mutations occur mostly in the C-terminal end, which interacts with the PI3 kinase domain. This domain is involved with acetylation and activation of ATM (40). DDR is impaired when the ATM protein is dysfunctional, and loss of this DDR mechanism designed for DSBs can possibly lead, over time, to the accumulation of mutations, which can, in theory initiate the process of tumorigenesis. For instance, germline point mutations in *ATM* result in increased risks of breast cancers, specifically those associated with the S49C and S707P mutations. Melanoma, prostate, and oropharyngeal cancers are specifically associated with the S49C mutation.

While thyroid or endocrine cancers are generally associated with the S707P mutation (41,42). Next-generation sequencing has also revealed somatic *ATM* mutations in many tumor types, including PDAC (Figure 2) (40).

Inactivating ATM Variants in Pancreatic Cancer

Multiple studies have reaffirmed the importance of *TP53*, *KRAS*, *CDKN2A* and *SMAD4* mutations in PDAC (7,11,43,44). Inherited risks of PDAC are also well established to be in large part due to germline mutations in *BRCA1/BRCA2* and *CDKN2A*, identified in 7.4% of familial pancreatic cancers (N=727(45)), as well as individuals affected by Lynch syndrome (mutations in the genes: *MLH1*, *MSH2*, *PMS2* and *MSH6*) (46). Additionally, a study of familial PDAC patients showed that deleterious *ATM* mutations were significantly higher than the control group suggesting ATM's role in malignancy (25). This knowledge has led to germline and somatic mutations in *ATM* as being identified and added to the catalog of predisposing gene mutations.

A genomic characterization of PDAC revealed 37% of the 71 samples carried alterations in DNA repair genes (6). This significant discovery has also been confirmed in a recent large PDAC profiling study that identified targetable alterations in 50% of 640 PDAC patients, of which 8.4% expressed *BRCA1/2* or *ATM* mutations (5). A review of the International Cancer Genome Consortium, a large database of sporadic PDACs, in 2015 identified *ATM* mutations in 9 – 18% of PDACs, with an average of 12% of the 591 samples (47). An additional large population study which identified the prevalence of homologous recombination related gene mutations in 15.4% of PDACs (48). This study also revealed that *ATM*, *ATR*, and *CHEK2* mutations are present in 1.3% out of fifty thousand tumors samples. These mutations were most prevalently identified in PDAC (48). Further genomic studies support the high prevalence of *ATM*, *CHEK2* and *ATR* mutations in PDAC (8). Our literature search, capturing 5,234 pancreatic cancer patients overall shows that the total prevalence of *ATM* mutations (germline or somatic) in PDAC is 6.4% (range 1 – 34%) (5,6,8,9,11,25,47–57). Importantly, in one study that showed that nearly 10% of PDAC patients carried a germline *ATM* mutation, in 44% of these patients a somatic second hit was identified (58). While this loss of heterozygosity (LOH) seems to occur frequently in tumors arising from patients with germline *ATM* mutations (e.g. as seen in breast and pancreatic cancers (59,60)), the necessity of LOH to confer therapeutic sensitivity (i.e. to platinum and DDR inhibitors, as discussed below) is uncertain.

ATM Deficiency: A Therapeutic Opportunity?

It is now well established that tumor cells with underlying defects in DDR are exquisitely sensitive to DNA-damaging agents, notably platinum, and more recently to PARP inhibitors in a phenomenon known as synthetic lethality (61). Similarly, inactivating mutations in *ATM* can also set up synthetic lethality in the presence of DNA damaging agents (62). Historically, ataxia telangiectasia patients were found to be profoundly radiosensitive at the chromosomal level suggesting the link between *ATM* and DNA repair (63). Pre-clinical data have demonstrated that knockdown of *ATM* results in radio-sensitization (64,65). Additional studies in the laboratory have demonstrated that *ATM* alterations in malignant cells can

sensitize cells to platinum drugs (44,66), and outside of platinum therapy, pre-clinical studies have also demonstrated ATM suppression in p53 deficient mouse fibroblasts sensitizes them to doxorubicin (67). Previous work has also demonstrated that ATM deficiency in *p53* deficient cell lines causes a modest increase in 5-FU sensitivity (68). Lastly, one study took advantage of *ATM*-mutated PDAC cells in a mouse model and showed that treatment with the PARP inhibitor, olaparib or the ATR inhibitor, VE-822 led to dramatic accumulation of DSBs and reduced tumor cell viability *in vitro* and *in vivo* (62). The authors noted the compensation of alternate signaling routes to bypass ATM deficiency, including ATR in the replicative stress response. Thus ATR inhibition was efficient in promoting intolerable mitotic damage, an effect that was enhanced when combined with gemcitabine (62).

The clinical experience in PDAC patients with confirmed *ATM*, *ATR* or *CHEK2* mutations is very limited, and focused on the efficacy of oxaliplatin-based chemotherapy. One case series (N=71) utilizing real-time whole exome sequencing demonstrated that a majority of patients with such mutations experienced a partial response or stable disease with oxaliplatin-based chemotherapy (6). In this case series, 80% of those with *ATM*, *ATR* or *CHEK2* mutations were treated with an oxaliplatin-based chemotherapy and 62.5% demonstrated partial response or stable disease on first follow-up scans (6). Another small study (N=13) demonstrated a 37.5% response rate to oxaliplatin-based chemotherapy regimens in patients with DDR mutated tumors (69). There was also a significantly longer progression free survival compared to those patients whose tumors were DDR-non-mutated (20.8 months vs 1.7 months respectively p=0.049) (69). Specifically, four of thirty patients had known pathogenic *ATM* mutations, with at least one patient experiencing a prolonged partial response of nearly 40 months on 5-FU, irinotecan, and oxaliplatin (FOLFIRINOX) (69). There are currently multiple ongoing trials targeting ATM-deficient tumors, including and especially with PARP inhibitors (Table 1).

Since ATM, ATR and CHK1 are all important for resolving DNA damage (Figure 1), utilizing an underlying DDR defect and inducing synthetic lethality by inhibiting an additional kinase is an innovative way to induce cancer cell death. The use of small molecule inhibitors of ATM, ATR and CHK1 are promising avenues of cancer treatment due to the malignant cells' rapid and unregulated cell division. There are currently phase I and II clinical trials utilizing ATM or ATR inhibitors as monotherapy as well as in combination with chemotherapy (70,71).

ATM Inhibitors

The first compound described to inhibit ATM was wortmannin (72), however, there are now a host of newer, more potent compounds that inhibit ATM. One of the newer generation of ATM inhibitors published in 2004 was KU55933. This compound was shown to inhibit downstream ATM phosphorylation after radiation, and it also enhanced responses to the topoisomerase inhibitors etoposide, camptothecins, and doxorubicin (73). A similar sensitization to topoisomerase inhibitors was later demonstrated with the ATM inhibitor, AZ31 which was shown to increase the efficacy of Irinotecan in resistant tumors in PDX models (74). KU60019 is another compound that was introduced in 2009 as an improved

analogue of KU55933 (75), and early work demonstrated that KU60019 is a potent radiosensitizer (75). This molecule is currently being studied in clear cell renal cell carcinoma in combination with another known sensitizing agent, CX4945, which is an inhibitor of the protein kinase CK2 (82). The rationale for this combination comes from a compound screen where CK2 and ATM inhibitors were found to be highly synergistic in renal cancer. Interestingly when CK2 inhibitors were tested in isogenic *ATM* proficient and deficient mouse cell lines there was little difference in downstream effectors of DNA repair such as AKT1 and BID although overall viability in the *ATM* proficient and deficient cell lines treated with CK2 inhibitors was not assessed (76). This brings to light an important point when comparing the efficacy of interventions performed in combination with *ATM* inhibitors, as compared to these same interventions performed in patients with *ATM* deficient tumors. The results may potentially be divergent as tumors with constitutive deficiency in *ATM* may have adapted to chronic loss of *ATM* function as opposed to acute loss as induced by *ATM* inhibitors. Conversely, other interventions may be both synergistic with *ATM* inhibitors and more potent in *ATM* deficient patients.

Beyond the pre-clinical explorations of *ATM* inhibitors, there are currently two *ATM* inhibitors in clinical trials which are being investigated in combination with other therapies (Table 1). AZD0156, an oral *ATM* inhibitor is currently in clinical trials in combination with olaparib or FOLFIRI (84). These combinations are rational since, as previously mentioned, *ATM* inhibitors have been shown to sensitize cells to PARP inhibitors, and also to both 5-FU and irinotecan (61,62,68). AZD1390, another oral *ATM* inhibitor that penetrates the blood-brain barrier is currently being tested in combination with radiation, given that radiation has been demonstrated to be more effective in *ATM* deficient cancers (65,77,78). Importantly in considering the potential adverse events for this trial, knockout of *ATM* in healthy tissue as compared to cancerous tissue was shown to induce less radiation sensitivity (78). This work demonstrated that increased sensitivity to radiation through *ATM* inhibition was primarily seen in cells that were rapidly replicating. As *ATM* inhibitors are further explored in the clinic, it will, of course, be important to monitor the side effects of *ATM* inhibitors particularly in combination with other therapies.

Increased sensitivity of *ATM*-deficient tumors to PARP inhibitors has been previously shown (64,75,79), and in a clinical trial of 124 patients it has been demonstrated that dosing with olaparib and paclitaxel was more effective at increasing overall survival in patients with less *ATM* activity (HR, 0.35; 80% CI, 0.22 to 0.56; P = .002; median OS, not reached v 8.2 months) (80). Unfortunately, the subsequent Phase III trial with 525 patients did not enrich for patients with *ATM*-deficient tumors and was a negative study (81). Nevertheless, there are multiple ongoing trials of PARP inhibitor-based therapy targeting patients, at least in part, with *ATM*-deficient tumors (Table 1).

ATR Inhibitors

ATR is a phosphoinositide 3-kinase-related protein kinase that primarily responds to and repairs single-strand DNA breaks. It also shares functional sequences with *ATM* and DNA-PK, which respond to DSBs (29,82). Upstream protein phosphorylation by *ATM* and autophosphorylation at the T1989 site stimulates ATR activity as well as TopBP1 which

contains an ATR-activation domain to stimulate the kinase's activity (29,83). The ATR kinase responds to a wide array of cell stressors, maintains DNA's integrity during replication, and is essential for proliferating cell survival. In the rapidly dividing cancer cell, there exists a high degree of replicative stress, creating an environment in which, as preclinical research has shown, suppression of ATR activity further increases replication stress leading to cell death (84). Furthermore, while normal dividing cells utilize ATM dependent pathways for assistance in DNA repair, cancer cells, which are often deficient in ATM/p53 signaling, may rely solely on the ATR pathway for survival (67,85,86). This was demonstrated in genetically engineered mouse models of cancer, in which 90% genetic reduction of ATR expression suppressed the development of fibrosarcomas and acute myeloid leukemias with minimal side effects in normal tissues. This work affirmed the tumor selectivity of ATR inhibition (84). Moreover, inhibition of ATR selectively sensitizes tumor cells, but not normal cells, to radiation and chemotherapy (87).

Thus, small molecule inhibitors of ATR may be particularly potent in PDACs with somatic mutations in *ATM* given that the lack of ATM's function may lead to increased dependence on ATR, and ATR inhibition could thus significantly promote cancer cell death. The ATR inhibitor, VE-821, sensitizes cancer cells but not normal cells to chemotherapy (87), and these effects were synergistic in *ATM* deficient cells (87). Another ATR inhibitor, AZD6738, causes accumulation of DNA damage, S phase arrest, and apoptosis in *ATM* dysfunctional gastric cells while not affecting those with functional *ATM* (88). Similar pre-clinical studies also suggest synthetic lethality between ATR inhibition with VE-822 and *ATM* deficiency in PDAC as well as lung adenocarcinoma cell lines, reaffirming the actionable molecular dependencies on ATR (62,79). VE-822 has also been shown to potentially synergize with cisplatin in *ATM*-deficient esophageal squamous cells (89). This effect of potentiating the cytotoxicity of cisplatin and gemcitabine is also seen with AZD6738 in *ATM* deficient non-small cell lung cancer cells (90). Several ongoing trials of ATR inhibitor-based therapies are listed in Table 1.

CHK1 and CHK2 Inhibitors

Downstream to and activated by ATR is the checkpoint kinase 1 (CHK1) pathway. CHK1 promotes proteasomal degradation of CDC25A in response to genome stress (29). The combined activity of ATR, CHK1, and CDC25A results in cell cycle arrest and stabilization of replication stress at DNA forks. The inhibition of this complex leads to a decreased rate of fork progression, massive fork collapse in S phase cells and ultimately cell death (82). Preclinical studies utilizing the CHK1 inhibitors, MK8776 and LY2603618, with gemcitabine-based chemoradiation showed synergistic effects to induce apoptosis of PDAC cells (91,92). The combination of gemcitabine, a CHK1 inhibitor, PF-477736, and Lutetium-177-labeled anti-EGFR antibody lead to extensive DNA damage, apoptosis, and tumor degeneration in patient-derived xenografts (93). Additional preclinical studies with a tumor stem cell marker Doublecortin-like kinase 1 (*Dclk1*) inhibitor LRRK2-IN-1 (LRRK) showed decreased expression of phosphorylated Chk1 (94). This same study demonstrated the combination of gemcitabine with LRRK significantly reduced cell survival compared treatment with gemcitabine alone (94). Thus, CHK1 and *Dclk1* are both potential targets in *ATM*-deficient malignancies as they also play a large role in single-strand break DNA repair.

CHK1 activation is primarily dependent on ATR at stalled replication forks and single-strand DNA, whereas CHK2 is mainly activated by ATM induced by DNA DSBs. One preclinical study examined the antitumor effects of a CHK2 inhibitor, NSC109555, in combination with gemcitabine. This combination increased apoptosis in pancreatic cells (95). Clinical trials of CHK1/2 inhibitors are also listed in Table 1.

Conclusions

There are currently no FDA approved targeted therapies for patients with pancreatic cancer. However, genomic profiling of pancreatic adenocarcinomas is revealing therapeutically relevant alterations, and 17 – 25% of pancreatic cancers harbor mutations in the DDR pathway. Therapy targeted towards inhibiting the DNA damage response, including with PARP inhibitors is proving to be highly effective particularly in DDR deficient cancers, as has been established in *BRCA1/2* mutated cancers. However, DNA damage response is a highly complicated process, involving several overlapping pathways. It is reasonable to hypothesize that, depending upon the specific DDR mutation, there may be different optimal therapies to be utilized. PARP inhibitors are showing early promise in PDACs that harbor *BRCA1/2* or *PALB2* mutations, but consistently the most common DDR gene mutated in PDAC is actually *ATM*. It will be critical in the coming years to explore what DDR-targeted therapies might work best in ATM-deficient tumors. As with any therapeutic breakthrough, the future exploration of the complexity of the DDR pathway also justifies the need for a better understanding of compensatory and resistance mechanisms that may arise in the setting of ATM/ATR/CHK1 targeted therapies.

ATM-deficiency may provide sensitivity for other elements of conventional therapies for PDAC including radiation (96) and oxaliplatin. However, emerging targeted strategies, including immunotherapeutic combination approaches (97) will likely provide even better matches for ATM-deficient tumors. For example, mechanistically, it seems reasonable to consider that PARP inhibitors may be effective in treating *ATM*-deficient tumors. But potentially more promising might be the combination of a PARP inhibitor with an ATR inhibitor in ATM deficient PDAC – essentially exploiting a new node of synthetic lethality in the DNA damage response pathway. Similarly, there is a mechanistic reason to explore the role of CHK1 inhibition in ATM-deficient tumors. In both cases, understanding the need for inducing DNA damage with DNA damaging chemotherapy will be critical as well. There are several ongoing clinical trials as discussed above, but clinical trials in PDAC in which there is such a high unmet need, and where ATM deficiency is common, would be ideal.

Additionally, recent genetic studies have revealed that specific ATM genotypes correlate to susceptibility to different diseases including cancer, which may provide valuable clinical information with regards to early detection, the subtyping of, and the treatment of PDACs (98). These genetic studies may complement and/or be evaluated in published genetically engineered mouse models (47,62,99) that have identified ATM's various roles (i.e., EMT, genetic instability, and metastases) in the progression model of PDAC. Moving forward, the research community should evaluate novel agents and combination therapies discussed above in these isogenic, *in vivo* models with the ultimate aim of classifying each *ATM*

pathogenic genotype observed in patients with an optimally tailored, matched targeted therapeutic strategy.

Acknowledgments

Funding Sources:

J.R. Brody and M.J. Pishvaian are supported by an NIH-NCI R01 CA212600 grant and J.R. Brody is also supported by a NIH-NCI P30CA056036 core grant given to K. Knudsen. Research supported by the 2015 Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant, Grant Number 15-90-25-BROD to J.R. Brody and M.J. Pishvaian.

References

1. Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. *Cancer Med* 2016;5(9):2649–56 doi 10.1002/cam4.767. [PubMed: 27356493]
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014;74(11):2913–21 doi 10.1158/0008-5472.CAN-14-0155. [PubMed: 24840647]
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364(19):1817–25 doi 10.1056/NEJMoa1011923. [PubMed: 21561347]
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013;369(18):1691–703 doi 10.1056/NEJMoa1304369. [PubMed: 24131140]
5. Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, et al. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. *Clin Cancer Res* 2018;24(20):5018–27 doi 10.1158/1078-0432.CCR-18-0531. [PubMed: 29954777]
6. Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, et al. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. *Cancer Discov* 2018;8(9):1096–111 doi 10.1158/2159-8290.CD-18-0275. [PubMed: 29903880]
7. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016;531(7592):47–52 doi 10.1038/nature16965. [PubMed: 26909576]
8. Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. *Nat Commun* 2015;6:6744 doi 10.1038/ncomms7744. [PubMed: 25855536]
9. Lowery MA, Jordan EJ, Basturk O, Ptashkin RN, Zehir A, Berger MF, et al. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. *Clin Cancer Res* 2017;23(20):6094–100 doi 10.1158/1078-0432.CCR-17-0899. [PubMed: 28754816]
10. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat Genet* 2015;47(10):1168–78 doi 10.1038/ng.3398. [PubMed: 26343385]
11. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012;491(7424):399–405 doi 10.1038/nature11547. [PubMed: 23103869]
12. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. *Nat Rev Cancer* 2008;8(3):193–204 doi 10.1038/nrc2342. [PubMed: 18256616]
13. Chen CC, Feng W, Lim PX, Kass EM, Jasin M. Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. *Annu Rev Cancer Biol* 2018;2:313–36 doi 10.1146/annurev-cancerbio-030617-050502. [PubMed: 30345412]

14. Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. *Nat Med* 2018;24(5):628–37 doi 10.1038/s41591-018-0009-7. [PubMed: 29713086]
15. Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. *Br J Cancer* 2014;111(6):1132–8 doi 10.1038/bjc.2014.418. [PubMed: 25072261]
16. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *J Clin Oncol* 2015;33(3):244–50 doi 10.1200/JCO.2014.56.2728. [PubMed: 25366685]
17. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *N Engl J Med* 2017;377(6):523–33 doi 10.1056/NEJMoa1706450. [PubMed: 28578601]
18. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med* 2018;379(8):753–63 doi 10.1056/NEJMoa1802905. [PubMed: 30110579]
19. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *N Engl J Med* 2015;373(18):1697–708 doi 10.1056/NEJMoa1506859. [PubMed: 26510020]
20. Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. *Gynecol Oncol* 2016;140(2):199–203 doi 10.1016/j.ygyno.2015.12.020. [PubMed: 26723501]
21. Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, et al. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. *JCO Precis Oncol* 2018;2018 doi 10.1200/PO.17.00316.
22. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science* 1995;268(5218):1749–53. [PubMed: 7792600]
23. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. *Oncogene* 2006;25(43):5898–905 doi 10.1038/sj.onc.1209879. [PubMed: 16998504]
24. Cavaciuti E, Lauge A, Janin N, Ossian K, Hall J, Stoppa-Lyonnet D, et al. Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. *Genes Chromosomes Cancer* 2005;42(1):1–9 doi 10.1002/gcc.20101. [PubMed: 15390180]
25. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov* 2012;2(1):41–6 doi 10.1158/2159-8290.CD-11-0194. [PubMed: 22585167]
26. Grant RC, Al-Sukhni W, Borgida AE, Holter S, Kanji ZS, McPherson T, et al. Exome sequencing identifies nonsegregating nonsense ATM and PALB2 variants in familial pancreatic cancer. *Hum Genomics* 2013;7:11 doi 10.1186/1479-7364-7-11. [PubMed: 23561644]
27. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *N Engl J Med* 2016;375(5):443–53 doi 10.1056/NEJMoa1603144. [PubMed: 27433846]
28. Angele S, Falconer A, Edwards SM, Dork T, Bremer M, Moullan N, et al. ATM polymorphisms as risk factors for prostate cancer development. *Br J Cancer* 2004;91(4):783–7 doi 10.1038/sj.bjc.6602007. [PubMed: 15280931]
29. Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. *Mol Cell* 2017;66(6):801–17 doi 10.1016/j.molcel.2017.05.015. [PubMed: 28622525]
30. Lee SS, Bohrsen C, Pike AM, Wheelan SJ, Greider CW. ATM Kinase Is Required for Telomere Elongation in Mouse and Human Cells. *Cell Rep* 2015;13(8):1623–32 doi 10.1016/j.celrep.2015.10.035. [PubMed: 26586427]
31. Seidel JJ, Anderson CM, Blackburn EH. A novel Tel1/ATM N-terminal motif, TAN, is essential for telomere length maintenance and a DNA damage response. *Mol Cell Biol* 2008;28(18):5736–46 doi 10.1128/MCB.00326-08. [PubMed: 18625723]

32. Palazzo L, Della Monica R, Visconti R, Costanzo V, Grieco D. ATM controls proper mitotic spindle structure. *Cell Cycle* 2014;13(7):1091–100 doi 10.4161/cc.27945. [PubMed: 24553124]
33. Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates JR 3rd, et al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. *Cell* 1998;93(3):477–86. [PubMed: 9590181]
34. You Z, Chahwan C, Bailis J, Hunter T, Russell P. ATM activation and its recruitment to damaged DNA require binding to the C terminus of Nbs1. *Mol Cell Biol* 2005;25(13):5363–79 doi 10.1128/MCB.25.13.5363-5379.2005. [PubMed: 15964794]
35. Sun Y, Xu Y, Roy K, Price BD. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. *Mol Cell Biol* 2007;27(24):8502–9 doi 10.1128/MCB.01382-07. [PubMed: 17923702]
36. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. *Nature* 2003;421(6922):499–506 doi 10.1038/nature01368. [PubMed: 12556884]
37. Lau WC, Li Y, Liu Z, Gao Y, Zhang Q, Huen MS. Structure of the human dimeric ATM kinase. *Cell Cycle* 2016;15(8):1117–24 doi 10.1080/15384101.2016.1158362. [PubMed: 27097373]
38. Lavin MF, Kozlov S. ATM activation and DNA damage response. *Cell Cycle* 2007;6(8):931–42 doi 10.4161/cc.6.8.4180. [PubMed: 17457059]
39. Mochan TA, Venere M, DiTullio RA Jr., Halazonetis TD. 53BP1 and NFB1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. *Cancer Res* 2003;63(24):8586–91. [PubMed: 14695167]
40. Choi M, Kipps T, Kurzrock R. ATM Mutations in Cancer: Therapeutic Implications. *Mol Cancer Ther* 2016;15(8):1781–91 doi 10.1158/1535-7163.MCT-15-0945. [PubMed: 27413114]
41. Stredrick DL, Garcia-Closas M, Pineda MA, Bhatti P, Alexander BH, Doody MM, et al. The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. *Hum Mutat* 2006;27(6):538–44 doi 10.1002/humu.20323. [PubMed: 16652348]
42. Dombrowsky SL, Weischer M, Allin KH, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Risk of cancer by ATM missense mutations in the general population. *J Clin Oncol* 2008;26(18):3057–62 doi 10.1200/JCO.2007.14.6613. [PubMed: 18565893]
43. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008;321(5897):1801–6 doi 10.1126/science.1164368. [PubMed: 18772397]
44. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature* 2015;518(7540):495–501 doi 10.1038/nature14169. [PubMed: 25719666]
45. Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. *Genet Med* 2015;17(7):569–77 doi 10.1038/gim.2014.153. [PubMed: 25356972]
46. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA* 2009;302(16):1790–5 doi 10.1001/jama.2009.1529. [PubMed: 19861671]
47. Russell R, Perkhof L, Liebau S, Lin Q, Lechel A, Feld FM, et al. Loss of ATM accelerates pancreatic cancer formation and epithelial-mesenchymal transition. *Nat Commun* 2015;6:7677 doi 10.1038/ncomms8677. [PubMed: 26220524]
48. Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, et al. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. *JCO Precis Oncol* 2018;2018 doi 10.1200/PO.17.00286.
49. Murphy SJ, Hart SN, Lima JF, Kipp BR, Klebig M, Winters JL, et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. *Gastroenterology* 2013;145(5):1098–109 e1 doi 10.1053/j.gastro.2013.07.049. [PubMed: 23912084]
50. Kim H, Saka B, Knight S, Borges M, Childs E, Klein A, et al. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. *Clin Cancer Res* 2014;20(7):1865–72 doi 10.1158/1078-0432.CCR-13-1239. [PubMed: 24486587]

51. Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. *Gastroenterology* 2015;148(3):556–64 doi 10.1053/j.gastro.2014.11.042. [PubMed: 25479140]
52. Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, et al. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. *JAMA Oncol* 2017;3(6):774–83 doi 10.1001/jamaoncol.2016.3916. [PubMed: 27768182]
53. Shahda STK, Ibrahim A, et al. Homologous recombination deficiency (HRD) in patients with pancreatic cancer (PS) and response to chemotherapy American Society of Clinical Oncology Gastrointestinal Cancer Symposium, San Francisco, CA, January 21–23, 2016 (abstr 317) 2016.
54. Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, et al. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. *J Clin Oncol* 2017;35(30):3382–90 doi 10.1200/JCO.2017.72.3502. [PubMed: 28767289]
55. Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. *JAMA* 2018;319(23):2401–9 doi 10.1001/jama.2018.6228. [PubMed: 29922827]
56. Ohmoto A, Morizane C, Kubo E, Takai E, Hosoi H, Sakamoto Y, et al. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. *J Gastroenterol* 2018;53(10):1159–67 doi 10.1007/s00535-018-1466-y. [PubMed: 29667044]
57. Chaffee KG, Oberg AL, McWilliams RR, Majithia N, Allen BA, Kidd J, et al. Prevalence of germline mutations in cancer genes among pancreatic cancer patients with a positive family history. *Genet Med* 2018;20(1):119–27 doi 10.1038/gim.2017.85. [PubMed: 28726808]
58. Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. *Genet Med* 2018 doi 10.1038/s41436-018-0009-5.
59. Weigelt B, Bi R, Kumar R, Blecua P, Mandelker DL, Geyer FC, et al. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. *J Natl Cancer Inst* 2018;110(9):1030–4 doi 10.1093/jnci/djy028. [PubMed: 29506079]
60. Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, et al. Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. *J Natl Cancer Inst* 2018;110(10):1067–74 doi 10.1093/jnci/djy024. [PubMed: 29506128]
61. Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. *Science* 2017;355(6330):1152–8 doi 10.1126/science.aam7344. [PubMed: 28302823]
62. Perkhofor L, Schmitt A, Romero Carrasco MC, Ihle M, Hampp S, Ruess DA, et al. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. *Cancer Res* 2017;77(20):5576–90 doi 10.1158/0008-5472.CAN-17-0634. [PubMed: 28790064]
63. Taylor AM, Metcalfe JA, Oxford JM, Harnden DG. Is chromatid-type damage in ataxia telangiectasia after irradiation at G0 a consequence of defective repair? *Nature* 1976;260(5550):441–3. [PubMed: 1256587]
64. Wang L, et al. Abstract A93: Radiation-Induced Phosphorylation of ATDC via ATM/MAPKAP Kinase 2 Signaling Mediates Radioresistance of Pancreatic Cancer Cells. *Cancer Research*, vol 72, no 14 Supplement, 2012, doi:10.1158/1538-7445panca2012-a93 2012.
65. Ayars M, Eshleman J, Goggins M. Susceptibility of ATM-deficient pancreatic cancer cells to radiation. *Cell Cycle* 2017;16(10):991–8 doi 10.1080/15384101.2017.1312236. [PubMed: 28453388]
66. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. *Clin Cancer Res* 2014;20(3):764–75 doi 10.1158/1078-0432.CCR-13-2287. [PubMed: 24240112]
67. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. *Genes Dev* 2009;23(16):1895–909 doi 10.1101/gad.1815309. [PubMed: 19608766]

68. Fedier A, Schlamming M, Schwarz VA, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. *Ann Oncol* 2003;14(6):938–45. [PubMed: 12796033]
69. Kondo T, Kanai M, Kou T, Sakuma T, Mochizuki H, Kamada M, et al. Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer. *Oncotarget* 2018;9(28):19817–25 doi 10.18632/oncotarget.24865. [PubMed: 29731985]
70. O'Connor MJ. Targeting the DNA Damage Response in Cancer. *Mol Cell* 2015;60(4):547–60 doi 10.1016/j.molcel.2015.10.040. [PubMed: 26590714]
71. Brown JS, O'Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. *Cancer Discov* 2017;7(1):20–37 doi 10.1158/2159-8290.CD-16-0860. [PubMed: 28003236]
72. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. *Cancer Res* 1998;58(19):4375–82. [PubMed: 9766667]
73. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. *Cancer Res* 2004;64(24):9152–9 doi 10.1158/0008-5472.CAN-04-2727. [PubMed: 15604286]
74. Greene J, Nguyen A, Bagby SM, Jones GN, Tai WM, Quackenbush KS, et al. The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. *Oncotarget* 2017;8(67):110904–13 doi 10.18632/oncotarget.22920. [PubMed: 29340025]
75. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. *Mol Cancer Ther* 2009;8(10):2894–902 doi 10.1158/1535-7163.MCT-09-0519. [PubMed: 19808981]
76. Olsen BB, Fritz G, Issinger OG. Characterization of ATM and DNA-PK wild-type and mutant cell lines upon DSB induction in the presence and absence of CK2 inhibitors. *Int J Oncol* 2012;40(2):592–8 doi 10.3892/ijo.2011.1227. [PubMed: 21993375]
77. Neubauer S, Arutyunyan R, Stumm M, Dork T, Bendix R, Bremer M, et al. Radiosensitivity of ataxia telangiectasia and Nijmegen breakage syndrome homozygotes and heterozygotes as determined by three-color FISH chromosome painting. *Radiat Res* 2002;157(3):312–21. [PubMed: 11839094]
78. Moding EJ, Lee CL, Castle KD, Oh P, Mao L, Zha S, et al. Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium. *J Clin Invest* 2014;124(8):3325–38 doi 10.1172/JCI73932. [PubMed: 25036710]
79. Schmitt A, Knittel G, Welcker D, Yang TP, George J, Nowak M, et al. ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma. *Cancer Res* 2017;77(11):3040–56 doi 10.1158/0008-5472.CAN-16-3398. [PubMed: 28363999]
80. Bang YJ, Im SA, Lee KW, Cho JY, Song EK, Lee KH, et al. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. *J Clin Oncol* 2015;33(33):3858–65 doi 10.1200/JCO.2014.60.0320. [PubMed: 26282658]
81. Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017;18(12):1637–51 doi 10.1016/S1470-2045(17)30682-4. [PubMed: 29103871]
82. Saldívar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. *Nat Rev Mol Cell Biol* 2017;18(10):622–36 doi 10.1038/nrm.2017.67. [PubMed: 28811666]
83. Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG. Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. *J Biol Chem* 2007;282(24):17501–6 doi 10.1074/jbc.M701770200. [PubMed: 17446169]

84. Schoppy DW, Ragland RL, Gilad O, Shastri N, Peters AA, Murga M, et al. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. *J Clin Invest* 2012;122(1):241–52 doi 10.1172/JCI58928. [PubMed: 22133876]
85. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. *Nature* 2009;461(7267):1071–8 doi 10.1038/nature08467. [PubMed: 19847258]
86. Bolt J, Vo QN, Kim WJ, McWhorter AJ, Thomson J, Hagensee ME, et al. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. *Oral Oncol* 2005;41(10):1013–20 doi 10.1016/j.oraloncology.2005.06.003. [PubMed: 16139561]
87. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. *Nat Chem Biol* 2011;7(7):428–30 doi 10.1038/nchembio.573. [PubMed: 21490603]
88. Min A, Im SA, Jang H, Kim S, Lee M, Kim DK, et al. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. *Mol Cancer Ther* 2017;16(4):566–77 doi 10.1158/1535-7163.MCT-16-0378. [PubMed: 28138034]
89. Shi Q, Shen LY, Dong B, Fu H, Kang XZ, Yang YB, et al. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. *Cancer Lett* 2018;432:56–68 doi 10.1016/j.canlet.2018.06.010. [PubMed: 29890208]
90. Vendetti FP, Lau A, Schamus S, Conrads TP, O'Connor MJ, Bakkenist CJ. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. *Oncotarget* 2015;6(42):44289–305 doi 10.18632/oncotarget.6247. [PubMed: 26517239]
91. Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. *Clin Cancer Res* 2013;19(16):4412–21 doi 10.1158/1078-0432.CCR-12-3748. [PubMed: 23804422]
92. Liang M, Zhao T, Ma L, Guo Y. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. *Oncol Rep* 2018;39(3):1322–30 doi 10.3892/or.2017.6168. [PubMed: 29286153]
93. Al-Ejeh F, Pajic M, Shi W, Kalimutho M, Miranda M, Nagrial AM, et al. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2014;20(12):3187–97 doi 10.1158/1078-0432.CCR-14-0048. [PubMed: 24838526]
94. Kawamura D, Takemoto Y, Nishimoto A, Ueno K, Hosoyama T, Shirasawa B, et al. Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells. *Oncol Rep* 2017;38(5):3238–44 doi 10.3892/or.2017.5974. [PubMed: 29048622]
95. Duong HQ, Hong YB, Kim JS, Lee HS, Yi YW, Kim YJ, et al. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine. *J Cell Mol Med* 2013;17(10):1261–70 doi 10.1111/jcmm.12101. [PubMed: 23855452]
96. Hallahan D ATM Inhibition Sensitizes Tumors to High-Dose Irradiation. *Cancer Res* 2019;79(4):704–5 doi 10.1158/0008-5472.CAN-18-4072. [PubMed: 30770366]
97. Sen T, Rodriguez BL, Chen L, Della Corte C, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer. *Cancer Discov* 2019 doi 10.1158/2159-8290.CD-18-1020.
98. van Os NJH, Chessa L, Weemaes CMR, van Deuren M, Fievet A, van Gaalen J, et al. Genotype-phenotype correlations in ataxia telangiectasia patients with ATM c.3576G>A and c.8147T>C mutations. *J Med Genet* 2019 doi 10.1136/jmedgenet-2018-105635.
99. Drosos Y, Escobar D, Chiang MY, Roys K, Valentine V, Valentine MB, et al. ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer. *Sci Rep* 2017;7(1):11144 doi 10.1038/s41598-017-11661-8. [PubMed: 28894253]




Figure 1: ATM functions and other related pathways for DNA repair.

ATM is recruited to DSBs by the MRN complex through direct interaction of NSB1 with ATM's HEAT repeats. ATM is then activated through autophosphorylation, and acetylation by TIP60, this activation allows ATM to dissociate to the active monomeric state. ATM monomers can then signal for DNA repair through BRCA1 and γ -H2AX. ATM can also signal for cell cycle arrest and/or apoptosis through the activation of p53 through direct phosphorylation and indirect activation through CHK2 and MDM2. In parallel, ATR is recruited to long stretches of single strand DNA caused by single strand breaks, the resection of DSBs, or replication stress. PARP1 is another factor that is critical for the repair of single strand breaks.




Figure 2: ATM Structure-function domains and frequent mutations in PDAC.

ATM has several important domains that are critical for ATM function as either a monomer, dimer or both. The TAN domain is critical for telomerase function and recruitment to DSBs. This recruitment is also dependent on interactions between the ATM HEAT repeats and NBS1 (part of the MRN complex)(31,34). The FAT domain normally inhibits the kinase activity as a dimer, but after DNA damage induced autophosphorylation at S1981 and subsequent dissociation of the dimer the kinase domain becomes active (36). The FATC domain is critical for interaction with TIP60, TIP60 acetylation of ATM at K3016 is necessary for ATM activation. Mutational analysis of PDAC patients with *ATM* mutations from Cbio-portal (date of accession 01/21/2019) did not show significant clustering or hotspot mutations in *ATM*, but the number of patients was low (N=34).

Table 1:**ATM-relevant trials.**

The table summarizes currently open clinical trials that directly or indirectly target ATM-deficient tumors. The trials were captured from a search on clinicaltrials.gov on 03/02/2019. Clinical trials that potentially accept pancreatic cancer patients are **in bold type**.

DDR Target	Drug name	NCT Identifier	Phase	Study Size	ATM Status Considered	Study Title (Pancreatic cancer eligible trials are in bold)
ATM	AZD0156		I	83	No	Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer. (AToM)
	AZD1390		I	132	No	A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
ATR	M6620 (VX-970)		I	60	No	Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
	M6620 (VX-970)		I	51	No	VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
	M6620 (VX-970)		II	28	Exploratory Objective	ATR Kinase Inhibitor M6620 and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
	M6620 (VX-970)		II	130	No	ATR Kinase Inhibitor VX-970 and Carboplatin With or Without Docetaxel in Treating Participants With Metastatic Castration-Resistant Prostate Cancer
	M6620 (VX-970)		II	90	No	Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor M6620 in Treating Patients With Metastatic Urothelial Cancer
	M6620 (VX-970)		II	70	No	Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
	M6620 (VX-970)		I	111	No	Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
	M6620 (VX-970)		I/II	70	No	Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Cancers Amd Extrapulmonary Small Cell Cancers
	M6620 (VX-970)		I	65	No	M6620 Plus Standard Treatment in Oesophageal and Other Cancer (CHARIOT)
	M6620 (VX-970)		I	45	No	M6620, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma
	M6620 (VX-970)		I	46	No	VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
	M6620 (VX-970)		II	223	Yes	M6620 (VX-970) in Selected Solid Tumors
	AZD6738		II	68	No	Phase II Trial of AZD6738 Alone and in Combination With Olaparib
AZD6738		II	86	No	Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)	

DDR Target	Drug name	NCT Identifier	Phase	Study Size	ATM Status Considered	Study Title (Pancreatic cancer eligible trials are in bold)
CHK1/2	AZD6738		II	47	No	Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
	AZD6738		I/II	62	No	A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
	AZD6738		I	50	No	AZD6738 & Gemcitabine as Combination Therapy (ATRiUM)
	AZD6738		Ib	52	No	AZD6738 for Patients With Progressive MDS or CMML
	AZD6738		I	250	Yes	Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents
	BAY1895344		I	219	Yes	First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
	Prexasertib		II	50	Yes	A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
	Prexasertib		I	24	No	Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
	Prexasertib		I	28	No	A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
	Prexasertib		II	153	No	A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
	Prexasertib		I	65	No	Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
	Prexasertib		I	28	No	Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
	SRA737		I/II	170	Chk1 or ATR or other related gene	A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
SRA737		I/II	140	Yes	A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer	
<i>Additional Trials Targeting ATM-Deficient Tumors</i>						
PARP	Olaparib		II	64	No	OLAParib Combinations (OLAPCO)
	Olaparib		Ib	102	Yes	Copanlisib, Olaparib, and Durvalumab in Treating Patients With Metastatic or Unresectable Solid Tumors
	Olaparib		II	28	Yes	Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations (SUKSES-B)
	Olaparib		II	70	Yes	Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
	Olaparib		II	20	Yes	Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)
	Olaparib		Pilot	15	Yes	Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
	Olaparib		II	60	Yes	Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

DDR Target	Drug name	NCT Identifier	Phase	Study Size	ATM Status Considered	Study Title (Pancreatic cancer eligible trials are in bold)
	Olaparib		I/II	427	No	A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)
	Talozaparib		II	200	Yes	Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
	Talozaparib		II	150	Yes	Study of the PARP Inhibitor BMN 673 in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)
	Talozaparib		Ib/2	242	No	Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
	Talozaparib		II	64	Yes	Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
	Talozaparib		II	58	Yes	Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type & Triple-Neg /HER2-Negative Breast Cancer / SolidTumors
	Niraparib		I	146	Yes	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
	Niraparib		II	47	Yes	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
	Rucaparib		II	360	Yes	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript